MAP Stock Overview
Provides microbiome testing and analysis services for clinicians, consumers, and research customers in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, and Singapore.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Microba Life Sciences Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.16 |
| 52 Week High | AU$0.40 |
| 52 Week Low | AU$0.14 |
| Beta | 2.76 |
| 11 Month Change | -20.00% |
| 3 Month Change | -23.81% |
| 1 Year Change | -50.77% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -54.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| MAP | AU Healthcare | AU Market | |
|---|---|---|---|
| 7D | -5.9% | -2.3% | -0.3% |
| 1Y | -50.8% | -20.2% | 8.3% |
Return vs Industry: MAP underperformed the Australian Healthcare industry which returned -20.7% over the past year.
Return vs Market: MAP underperformed the Australian Market which returned 8.3% over the past year.
Price Volatility
| MAP volatility | |
|---|---|
| MAP Average Weekly Movement | 8.3% |
| Healthcare Industry Average Movement | 5.4% |
| Market Average Movement | 8.2% |
| 10% most volatile stocks in AU Market | 16.3% |
| 10% least volatile stocks in AU Market | 3.2% |
Stable Share Price: MAP's share price has been volatile over the past 3 months.
Volatility Over Time: MAP's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | n/a | Luke Reid | microba.com |
Microba Life Sciences Limited provides microbiome testing and analysis services for clinicians, consumers, and research customers in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, and Singapore. The company operates through two segments, Testing Services, and Research and Development. It offers pathology, therapeutics, and diagnostics services based on the human gut microbiome; testing and data analysis services for personal and research testing; and data-driven therapeutics platform that develops novel monoclonal microbial cell therapies for inflammatory bowel disease, cancer immunotherapy, and autoimmune diseases, as well as Databank for health and biome data.
Microba Life Sciences Limited Fundamentals Summary
| MAP fundamental statistics | |
|---|---|
| Market cap | AU$71.66m |
| Earnings (TTM) | -AU$18.49m |
| Revenue (TTM) | AU$6.54m |
11.0x
P/S Ratio-3.9x
P/E RatioIs MAP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MAP income statement (TTM) | |
|---|---|
| Revenue | AU$6.54m |
| Cost of Revenue | AU$3.50m |
| Gross Profit | AU$3.04m |
| Other Expenses | AU$21.53m |
| Earnings | -AU$18.49m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.041 |
| Gross Margin | 46.55% |
| Net Profit Margin | -282.65% |
| Debt/Equity Ratio | 0.2% |
How did MAP perform over the long term?
See historical performance and comparison